Liege, Belgium, 25 November 2022 – 18:55 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, takes note of the market reaction to the evolution of the Company’s share price, but wants to reaffirm its strategic intentions concerning its product-candidate Donesta®. The Company is therefore maintaining the operational calendar as announced on September 23rd at the half-year 2022 results.
Negotiations with potential partners to commercialize, the product-candidate, Donesta® are ongoing. The objective of announcing binding offers at the end of the year is maintained. The receipt of the first safety data from the Donesta® Phase 3 Study conducted in the United States and Canada is also expected by the end of 2022.